TherapeuticsMD Inc

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

88338N107
SEDOL

B6WXT12
CIK

0000025743

www.therapeuticsmd.com
LEI:
New: Infographics X-Lab
FIGI: BBG00JVKBQ81
TXMD

TherapeuticsMD Inc
GICS: - · Sector: Pharmaceuticals · Sub-Sector: -
AI
PROFILER
NAME
TherapeuticsMD Inc
ISIN
US88338N1072
TICKER
TXMD
MIC
XNAS
REUTERS
TXMD.OQ
BLOOMBERG
TXMD US
F&G: 66
6.214,72 S&P · 18,65 Vola-Index · 106.234,01 BTC · 1,17994 EURUSD
FOR INVESTORS
FOR TRADERS
Securities Trading
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Tue, 13.05.2025       TherapeuticsMD
US88338N1072

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(636) thousand, or $(0.06)...
Thu, 27.03.2025       TherapeuticsMD
US88338N1072

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per ...
Tue, 12.11.2024       TherapeuticsMD
US88338N1072

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) tho...
Mon, 12.08.2024       TherapeuticsMD
US88338N1072

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) milli...
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

BARRISTA SMART * AD

P R O D U C T   S U G G E S T I O N S